<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">LORAZEPAM <img border="0" src="../images/pr.gif"/></span><br/>(lor-a'ze-pam)<br/><span class="topboxtradename">Ativan<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">anxiolytic</span>; <span class="classification">sedative-hypnotic</span>; <span class="classification">benzodiazepine</span><br/><b>Pregnancy Category: </b>D<br/><b>Controlled Substance: </b>Schedule IV<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.5 mg, 1 mg, 2 mg tablets; 2 mg/mL oral solution; 2 mg/mL, 4 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Most potent of the available benzodiazepines. Effects (anxiolytic, sedative, hypnotic, and skeletal muscle relaxant) are mediated
         by the inhibitory neurotransmitter GABA. Action sites: thalamic, hypothalamic, and limbic levels of CNS.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Antianxiety agent that also causes mild suppression of REM sleep, while increasing total sleep time.</p>
<h1><a name="uses">Uses</a></h1>
<p>Management of anxiety disorders and for short-term relief of symptoms of anxiety. Also used for preanesthetic medication to
         produce sedation and to reduce anxiety and recall of events related to day of surgery; for management of status epilepticus.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Chemotherapy-induced nausea and vomiting.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Known sensitivity to benzodiazepines; acute narrow-angle glaucoma; primary depressive disorders or psychosis; children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Renal or hepatic impairment; organic brain syndrome; myasthenia gravis; narrow-angle glaucoma; suicidal tendency; GI disorders;
         older adult and debilitated patients; limited pulmonary reserve.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Antianxiety</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 26 mg/d in divided doses (max: 10 mg/d)<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> 0.51 mg/d (max: 2 mg/d)<br/><span class="rdage">Child:</span> <span class="rdroute">PO/IV</span> 0.05 mg/kg q48h (max: 2 mg/dose)<br/><br/><span class="indicationtitle">Insomnia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 24 mg at bedtime<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> 0.51 mg h.s.<br/><br/><span class="indicationtitle">Premedication</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 24 mg (0.05 mg/kg) at least 2 h before surgery <span class="rdroute">IV</span> 0.044 mg/kg up to 2 mg 1520 min before surgery<br/><span class="rdage">Child:</span> <span class="rdroute">PO/IV/IM</span> 0.05 mg/kg (range: 0.020.09 mg/kg)<br/><br/><span class="indicationtitle">Status Epilepticus</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 4 mg injected slowly at 2 mg/min, may repeat dose once if inadequate response after 10 min<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 0.1 mg/kg slow IV over 25 min (max: 4 mg/dose), may repeat with 0.05 mg in 1015 min if needed<br/><span class="rdage">Neonate:</span> <span class="rdroute">IV</span> 0.05 mg/kg over 25 min, may repeat in 1015 min<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Increase the evening dose when higher oral dosage is required, before increasing daytime doses.</li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Injected undiluted, deep into a large muscle mass.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>IV administration to neonates, infants, children: Verify correct IV concentration and rate of infusion with physician.</li>
<li>Patients &gt;50 y may have more profound and prolonged sedation with IV lorazepam (usual max: initial dose of 2 mg).</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Prepare lorazepam immediately before use. Dilute with an equal volume of sterile water, D5W, or NS.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Inject directly into vein or into IV infusion tubing at rate not to exceed 2 mg/min and with repeated aspiration to confirm
                  IV entry. Take extreme precautions to <small>PREVENT</small> intraarterial injection and perivascular extravasation.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Y-site:</span> <b>Idarubicin,</b> <b>omeprazole,</b> <b>ondansetron,</b> <b>sargramostim,</b> <b>sufentanil,</b> <b>TPN with albumin.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Keep parenteral preparation in refrigerator; do not freeze.</li>
<li>Do not use a discolored solution or one with a precipitate.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Usually disappear with continued medication or with reduced dosage. <span class="typehead">CNS:</span> Anterograde amnesia, <span class="speceff-common">drowsiness, sedation,</span> dizziness, weakness, unsteadiness, disorientation, depression, sleep disturbance, restlessness, confusion, hallucinations. <span class="typehead"> CV:</span> Hypertension or hypotension. <span class="typehead"> Special Senses:</span> Blurred vision, diplopia; depressed hearing. <span class="typehead">GI:</span> Nausea, vomiting, abdominal discomfort, anorexia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Alcohol,</b> <span class="classification">cns depressants</span>, <span class="classification">anticonvulsants</span> potentiate CNS depression; <b>cimetidine</b> increases lorazepam plasma levels, increases toxicity; lorazepam may decrease antiparkinsonism effects of <b>levodopa;</b> may increase <b>phenytoin</b> levels; smoking decreases sedative and antianxiety effects. <span class="typehead">Herbal:</span> <b>Kava-kava,</b> <b>valerian</b> may potentiate sedation. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Onset:</span> 15 min IV; 1530 min IM. <span class="typehead">Peak:</span> 6090 min IM; 2 h PO. <span class="typehead">Duration:</span> 1224 h. <span class="typehead">Distribution:</span> Crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Not metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 1020 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Have equipment for maintaining patent airway immediately available before starting IV administration.</li>
<li>IM or IV lorazepam injection of 24 mg is usually followed by a depth of drowsiness or sleepiness that permits patient
            to respond to simple instructions whether patient appears to be asleep or awake.
         </li>
<li>Supervise ambulation of older adult patients for at least 8 h after lorazepam injection to prevent falling and injury.</li>
<li>Lab tests: Assess CBC and liver function tests periodically for patients on long-term therapy.</li>
<li>Supervise patient who exhibits depression with anxiety closely; the possibility of suicide exists, particularly when there
            is apparent improvement in mood.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not drive or engage in other hazardous activities for a least 2448 h after receiving IM injection of lorazepam.</li>
<li>Do not drink large volumes of coffee. Anxiolytic effects of lorazepam can significantly be altered by caffeine.</li>
<li>Do not consume alcoholic beverages for at least 2448 h after an injection and avoid when taking an oral regimen.</li>
<li>Notify physician if daytime psychomotor function is impaired; a change in regimen or drug may be needed.</li>
<li>Terminate regimen gradually over a period of several days. Do not stop long-term therapy abruptly; withdrawal may be induced
            with feelings of panic, tonicclonic seizures, tremors, abdominal and muscle cramps, sweating, vomiting.
         </li>
<li>Do not self-medicate with OTC drugs; seek physician guidance.</li>
<li>Discuss discontinuation of drug with physician if you wish to become pregnant.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>